Pharma channel feed

The Supreme Court could over­turn the Chevron doc­trine. Here’s how that could hurt the FDA

Last year
FDA+
Law

Sun Phar­ma to buy out the rest of Taro's own­er­ship

Last year
Deals

J&J hosts celebri­ties and Blue Jack­et fash­ions dur­ing NY Fash­ion Week for prostate can­cer aware­ness

Last year
Marketing

'Peo­ple want vanil­la ice cream': CEO Anne Wo­j­ci­c­ki grap­ples with 23and­Me's dual iden­ti­ty

Last year
People

Bay­er to make sig­nif­i­cant cuts, rolls out new mod­el at 'ex­pense of many man­age­r­i­al em­ploy­ees'

Last year

EMD Serono lays out MS ther­a­pies' im­mune-sys­tem sup­pres­sion risks in new cam­paign

Last year
Marketing

Pfiz­er and BioN­Tech urge US patent re­view board to take on Mod­er­na's Covid patents

Last year
Coronavirus
Law

Eu­ro­pean Com­mis­sion launch­es new al­liance to ad­dress crit­i­cal drug short­ages

Last year
Manufacturing

Hu­mi­ra biosim­i­lar mar­ket re­mains stag­nant, with Ab­b­Vie los­ing on­ly 2% of mar­ket share, Sam­sung re­port shows

Last year

FDA+ roundup: Sen. Tillis goes af­ter Biden ad­min­is­tra­tion for sup­port­ing march-in rights

Last year
FDA+

Up­dat­ed: Seagen's ADC patent de­nied by US patent of­fice in bat­tle with Dai­ichi Sankyo

Last year
Law

As­traZeneca reshuf­fles Chi­na lead­er­ship, sets up bio­phar­ma group to mir­ror glob­al struc­ture

Last year
People
China

On­col­o­gy drugs lead 2023 new med­i­cines in Eu­rope — EMA re­port

Last year
FDA+

A decade af­ter its first FDA ap­proval, Take­da ex­pands la­bel of HyQvia to in­clude rare au­toim­mune dis­or­der

Last year
FDA+

Am­i­cus briefs fly in as IRA 'fair price' dead­line looms

Last year
Law

Mer­ck adds third cer­vi­cal can­cer nod for Keytru­da, bring­ing to­tal ap­provals to 39

Last year
R&D

No­vo Nordisk restarts ad­ver­tis­ing for obe­si­ty drug We­govy with new cam­paign

Last year
Marketing

Mar­ket­ingRx roundup: Phar­ma and biotech lead in salary sat­is­fac­tion; Pfiz­er cel­e­brates 175 years

Last year
Marketing

Ger­man trade union op­pos­es Bay­er’s busi­ness split pro­pos­al

Last year

Bio­Mar­in's chief com­mer­cial of­fi­cer step­ping down, search for suc­ces­sor be­gins

Last year
People

PhRMA, Eli Lil­ly, oth­er drug com­pa­nies push back on FDA's draft guid­ance about com­mu­ni­cat­ing off-la­bel use

Last year
FDA+

Econ­o­mists, health pol­i­cy ex­perts say J&J's IRA ar­gu­ments are 'over­ly sim­plis­tic'

Last year
Law

No­var­tis qui­et­ly used a PRV to speed the ap­proval of its new rare blood dis­or­der drug

Last year

J&J ex­tends ‘Save Legs’ cam­paign to dri­ve aware­ness of pe­riph­er­al artery dis­ease

Last year
Marketing
First page Previous page 79808182838485 Next page Last page
A service from the Financial Times